Rate of Correction and All-Cause Mortality in Patients With Severe Hypernatremia.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
05 09 2023
05 09 2023
Historique:
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Hypernatremia is common among hospitalized patients and is associated with high mortality rates. Current guidelines suggest avoiding fast correction rates but are not supported by robust data. To investigate whether there is an association between hypernatremia correction rate and patient survival. This retrospective cohort study examined data from all patients admitted to the Tel Aviv Medical Center between 2007 and 2021 who were diagnosed with severe hypernatremia (serum sodium ≥155 mmol/L) at admission or during hospitalization. Statistical analysis was performed from April 2022 to August 2023. Patients were grouped as having fast correction rates (>0.5 mmol/L/h) and slow correction rates (≤0.5 mmol/L/h) in accordance with current guidelines. All-cause 30-day mortality. A total of 4265 patients were included in this cohort, of which 2621 (61.5%) were men and 343 (8.0%) had fast correction rates; the median (IQR) age at diagnosis was 78 (64-87) years. Slow correction was associated with higher 30-day mortality compared with fast correction (50.7% [1990 of 3922] vs 31.8% [109 of 343]; P < .001). These results remained significant after adjusting for demographics (age, gender), Charlson comorbidity index, initial sodium, potassium, and creatinine levels, hospitalization in an ICU, and severe hyperglycemia (adjusted odds ratio [aOR], 2.02 [95% CI, 1.55-2.62]), regardless of whether hypernatremia was hospital acquired (aOR, 2.19 [95% CI, 1.57-3.05]) or documented on admission (aOR, 1.64 [95% CI, 1.06-2.55]). There was a strong negative correlation between absolute sodium correction during the first 24 hours following the initial documentation of severe hypernatremia and 30-day mortality (Pearson correlation coefficient, -0.80 [95% CI, -0.93 to -0.50]; P < .001). Median (IQR) hospitalization length was shorter for fast correction vs slow correction rates (5.0 [2.1-14.9] days vs 7.2 [3.5-16.1] days; P < .001). Prevalence of neurological complications was comparable for both groups, and none were attributed to fast correction rates of hypernatremia. This cohort study of patients with severe hypernatremia found that rapid correction of hypernatremia was associated with shorter hospitalizations and significantly lower patient mortality without any signs of neurologic complications. These results suggest that physicians should consider the totality of evidence when considering the optimal rates of correction for patients with severe hypernatremia.
Identifiants
pubmed: 37768662
pii: 2809955
doi: 10.1001/jamanetworkopen.2023.35415
pmc: PMC10539989
doi:
Substances chimiques
Sodium
9NEZ333N27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2335415Références
Pediatr Emerg Care. 2013 Jul;29(7):808-13
pubmed: 23823259
Intensive Care Med. 1979 Mar;5(1):27-31
pubmed: 35558
Am J Med Sci. 2011 May;341(5):356-60
pubmed: 21358313
PLoS Med. 2005 Aug;2(8):e124
pubmed: 16060722
BMC Nephrol. 2014 Feb 21;15:37
pubmed: 24559470
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Ann Intensive Care. 2016 Dec;6(1):22
pubmed: 26983857
Nat Rev Dis Primers. 2021 Jul 15;7(1):52
pubmed: 34267223
Clin J Am Soc Nephrol. 2019 May 7;14(5):645-647
pubmed: 31064771
Am J Kidney Dis. 2007 Dec;50(6):952-7
pubmed: 18037096
Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):189-203
pubmed: 27156758
Am Fam Physician. 2015 Mar 1;91(5):299-307
pubmed: 25822386
Semin Nephrol. 1998 Jan;18(1):20-30
pubmed: 9459286
JAMIA Open. 2020 Dec 14;3(4):557-566
pubmed: 33623891
Am J Kidney Dis. 2018 Mar;71(3):436-440
pubmed: 29277507
Clin J Am Soc Nephrol. 2017 May 8;12(5):799-806
pubmed: 28450414
Clin J Am Soc Nephrol. 2019 May 7;14(5):656-663
pubmed: 30948456
Lancet. 1998 Jul 18;352(9123):220-8
pubmed: 9683227